Innovative vaccines for a healthier world
Interview with CEO Bent Frandsen
Next Event
-
Tue23Apr2024Thu25Apr2024London, UK
Immune-Oncology Summit Europe
We look forward to attending Cambridge Healthtech Institute's Inaugural event - Therapeutic Cancer Vaccines - showcasing Immunological Advances for Cancer Treatment.
ExpreS2ion CSO Farshad Guirakhoo will be speaking on Preclinical Proof Of Concept Studies of a Novel Human HER-2 Virus Like Particle as a Vaccine Candidate for Human Breast Cancers on April 23 at 4:30pm in the session on Peptide-Based Vaccines.
Learn more on Immune-Oncology Europe.
Latest News
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023
Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the Board of Directors of ExpreS2ion has resolved to postpone the Company's annual general meeting and consequently also the publication of the annual report for 2023 due to administrative and practical reasons.
Read moreExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate
Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate.
Read moreExpreS2ion to present in investor and R&D events in March
Hørsholm, Denmark, 15 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.
Read more